Relmada Therapeutics Inc (RLMD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Relmada Therapeutics Inc (RLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11487
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treatment of neuropathic pain; REL-1028 BuTab, an oral tablet form of buprenorphine; REL-1015 LevoCap ER, an abuse resistant form of broad spectrum opioid levorphanol; and REL-1021 MepiGel, a topical gel dosage form of local anesthetic mepivacaine. It also develops analgesics and anti-arthritic medicines. The company offers products in the areas of chronic pain due to cancer, depression, ophthalmology, mitochondrial diseases, Rett syndrome, musculoskeletal disorders and peripheral neuropathy. Relmada Therapeutics is headquartered in New York, the US.

Relmada Therapeutics Inc (RLMD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Relmada Therapeutics Acquires Global Rights for Dextromethadone 10
Venture Financing 11
Camp Nine Raises USD11 Million in Venture Financing 11
Relmada Therapeutics Raises USD15 Million in Venture Financing 12
Relmada Therapeutics Raises US$8 Million In Series A Venture Financing 13
Relmada Raises US$0.2 Million In Venture Financing 14
Relmada Therapeutics Secures USD3 Million in Series A Funding Round 15
Equity Offering 16
Relmada Therapeutics Raises USD3.3 Million in Private Placement of Shares 16
Relmada Therapeutics Raises USD15.2 Million in Private Placement of Shares upon Exercise of Warrants 17
Camp Nine Raises USD2 Million in Private Placement of Shares 18
Debt Offering 19
Relmada Therapeutics to Raise USD6.8 Million in Private Placement of 7% Convertible Promissory Notes Due 2019 19
Acquisition 21
Camp Nine Acquires Relmada Therapeutics 21
Relmada Therapeutics Acquires Medeor 22
Relmada Therapeutics Inc – Key Competitors 23
Relmada Therapeutics Inc – Key Employees 24
Relmada Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Jun 28, 2017: Relmada Therapeutics appoints new chair of scientific advisory board 26
Jun 21, 2017: Relmada Therapeutics appoints new executive clinical advisor 27
Jun 15, 2017: Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors 28
Legal and Regulatory 29
May 18, 2017: Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company 29
Product News 30
01/24/2017: Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER 30
Other Significant Developments 31
Apr 16, 2018: BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Relmada Therapeutics Acquires Global Rights for Dextromethadone 10
Camp Nine Raises USD11 Million in Venture Financing 11
Relmada Therapeutics Raises USD15 Million in Venture Financing 12
Relmada Therapeutics Raises US$8 Million In Series A Venture Financing 13
Relmada Raises US$0.2 Million In Venture Financing 14
Relmada Therapeutics Secures USD3 Million in Series A Funding Round 15
Relmada Therapeutics Raises USD3.3 Million in Private Placement of Shares 16
Relmada Therapeutics Raises USD15.2 Million in Private Placement of Shares upon Exercise of Warrants 17
Camp Nine Raises USD2 Million in Private Placement of Shares 18
Relmada Therapeutics to Raise USD6.8 Million in Private Placement of 7% Convertible Promissory Notes Due 2019 19
Camp Nine Acquires Relmada Therapeutics 21
Relmada Therapeutics Acquires Medeor 22
Relmada Therapeutics Inc, Key Competitors 23
Relmada Therapeutics Inc, Key Employees 24
Relmada Therapeutics Inc, Subsidiaries 25

List of Figures
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Relmada Therapeutics Inc (RLMD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Skandinaviska Enskilda Banken AB:企業のM&A・事業提携・投資動向
    Skandinaviska Enskilda Banken AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Skandinaviska Enskilda Banken AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Globus Medical Inc (GMED):企業の財務・戦略的SWOT分析
    Globus Medical Inc (GMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bankers Insurance Group:企業の戦略・SWOT・財務分析
    Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Visterra Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Visterra Inc (Visterra), formerly Parasol Therapeutics Inc is a clinical-stage biopharmaceutical company that develops antibody therapies for the treatment of infectious diseases. The company develops precision antibody-based biological medicines for infectious and non-infectious diseases. I …
  • K’s Holdings Corporation:企業の戦略・SWOT・財務情報
    K's Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary K's Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Desjardins Financial Security Life Assurance Company:企業の戦略・SWOT・財務情報
    Desjardins Financial Security Life Assurance Company - Strategy, SWOT and Corporate Finance Report Summary Desjardins Financial Security Life Assurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's st …
  • Bionomics Ltd (BNO)-製薬・医療分野:企業M&A・提携分析
    Summary Bionomics Ltd (Bionomics) is a biopharmaceutical company that focuses on the development of treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer's disease. Its pipeline products include BNC210, BNC 105, BNC101, and BNC375. The company uses var …
  • Tongaat Hulett Ltd (TON):企業の財務・戦略的SWOT分析
    Tongaat Hulett Ltd (TON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Dairy Farmers of America Inc:企業の戦略・SWOT・財務情報
    Dairy Farmers of America Inc - Strategy, SWOT and Corporate Finance Report Summary Dairy Farmers of America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Essar Power Ltd:企業の戦略的SWOT分析
    Essar Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • American Airlines Group Inc.:企業の戦略・SWOT・財務分析
    American Airlines Group Inc. - Strategy, SWOT and Corporate Finance Report Summary American Airlines Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Volkswagen AG (VOW3)-エネルギー分野:企業M&A・提携分析
    Summary Volkswagen AG (Volkswagen) is an automobile company involved in the design, development, production and sales of a wide range of vehicles and engines. It commercializes both passenger and commercial vehicles, including low consumption small cars and luxury class vehicles. The company sells i …
  • Shibuya Kogyo Co., Ltd.:企業の戦略・SWOT・財務情報
    Shibuya Kogyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shibuya Kogyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Trammo Inc:企業の戦略的SWOT分析
    Trammo Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Medicamen Biotech Ltd (531146):企業の財務・戦略的SWOT分析
    Medicamen Biotech Ltd (531146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Eco (Atlantic) Oil & Gas Ltd (EOG):企業の財務・戦略的SWOT分析
    Summary Eco (Atlantic) Oil & Gas Ltd (Eco) is an oil and gas exploration and development company. The company’s business activities include acquisition, identification, and development of upstream petroleum projects across Africa. The company's projects include cooper license-PEL 030, Sharon license …
  • Eurofins MWG Operon LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofins MWG Operon LLC (Eurofins) is a DNA sequencing service provider. The company offers DNA sequencing services, DNA synthesis products, and bioinformatic services. Its product categories comprise DNA and RNA synthesis, DNA sequencing, GENE synthesis and next gen seq. Eurofins provides n …
  • Koninklijke Philips N.V. (PHIA)-製薬・医療分野:企業M&A・提携分析
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical …
  • Medigard Ltd (MGZ)-医療機器分野:企業M&A・提携分析
    Summary Medigard Ltd (Medigard), formerly Medisafe Instruments Pty Ltd is a medical device company that designs and develops retractable safety medical devices. The company offers products such as auto-retractable syringe, manual retractable syringe, blood collection device, intravenous valve and fl …
  • Selecta Biosciences Inc (SELB):企業の財務・戦略的SWOT分析
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (S …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆